The peripheral blood mononuclear cells versus purified CD34⁺ cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis-a randomized single-blinded non-inferiority trial.

ABSTRACT:

Backgrounds

Patients with AICLI constitute a considerable proportion of NO-CLI patients and cannot be treated with surgical or endovascular treatment. Although cell therapy has shown satisfactory results in treating AICLI, research comparing the efficacy of treatment with the 2 kinds of cell products is rare. The aim of this study was to report the 5-year outcomes of a randomized single-blinded noninferiority trial (Number: NCT02089828) on peripheral blood mononuclear cells (PBMNCs) and purified CD34⁺ cells (PCCs) transplantation for treating angiitis-induced critical limb ischemia (AICLI).

Methods

A randomized single-blinded non-inferiority trial (Number: NCT02089828) was performed. Fifty patients were randomized 1:1 to the PBMNCs and PCCs groups. Efficacy outcom

SUBMITTER: Liu H 

PROVIDER: S-EPMC8935813 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature